Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Consensus Price Target of $15.14 According to Brokerages

Posted by George Bondi on Oct 4th, 2026

Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report) has been assigned a consensus rating of “Buy” from the ten research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $15.86.

A number of analysts have recently commented on the stock. Cantor Fitzgerald began coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating for the company. Wall Street Zen raised Inventiva from a “sell” rating to a “hold” rating in a report on Saturday. Guggenheim raised their target price on Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Finally, Truist Financial raised their price objective on shares of Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a report on Friday.

Read Our Latest Research Report on Inventiva

Institutional Investors Weigh In On Inventiva

A number of hedge funds have recently modified their holdings of the business. Engineers Gate Manager LP lifted its position in Inventiva by 155.5% during the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after purchasing an additional 43,280 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Inventiva during the 4th quarter valued at about $603,000. Seven Fleet Capital Management LP bought a new position in shares of Inventiva during the 1st quarter valued at approximately $1,111,000. Eventide Asset Management LLC bought a new position in shares of Inventiva during the 4th quarter valued at approximately $1,155,000. Finally, Propel Bio Management LLC purchased a new stake in Inventiva in the 4th quarter worth approximately $4,650,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Stock Up 2.9%

IVA opened at $3.56 on Thursday. The stock has a 50-day moving average price of $4.33 and a 200-day moving average price of $4.66. Inventiva has a 1 year low of $3.11 and a 1 year high of $7.98.

Inventiva (NASDAQ:IVA – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million for the quarter. As a group, equities research analysts expect that Inventiva will post -0.81 EPS for the current fiscal year.

About Inventiva

(Get Free Report)

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Dijon, France. The company develops oral small-molecule therapies for chronic metabolic and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an investigational pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.